PIVOZACT Trademark Information

Trademark by Novartis AG

Pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of oncological diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer

Classification Information

Use in Commerce Trademark - Applicant has provided proof of use of this mark in commerce to USPTO.

Primary Class: Class Details:
Class (005)
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: PIVOZACT
Status/Status Date:
REGISTERED
10/27/2020
Serial Number: 79286671
Filing Date: 4/17/2020
Registration Number: 6182314
Registration Date: 10/27/2020
Goods and Services: Pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of oncological diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer
Mark Description: NOT AVAILABLE
Type Of Mark: TradeMark
Published For Opposition Date: 8/11/2020
Last Applicant/Owner:
Novartis AG
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: (NOT AVAILABLE)
Correspondent:
Tepper & Eyster, PLLC
3724 Benson Drive
Raleigh NC 27609
Current Status:
REGISTERED
10/27/2020
Correspondent Search:
Maury M. Tepper, III is a correspondent of PIVOZACT trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on